News
Greenfield-based Elanco Health on Monday announced the $295 million cash sale of future U.S. royalty and milestone rights of ...
Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...
Less than a week after announcing it had a new CEO, privately held Creyon Bio Inc. began a licensing and research partnership ...
But Eli Lilly CEO David Ricks waved off the deal Thursday, telling Yahoo Finance in an interview that the company is focused ...
Eli Lilly is suing four telehealth companies selling compounded versions of the pharmaceutical giant's weight loss drug Zepbound and its diabetes treatment Mounjaro, the company's latest attempt ...
Hosted on MSN14d
Cantor Fitzgerald Initiates Coverage of Eli Lilly and (LLY) with Overweight RecommendationFintel reports that on April 22, 2025, Cantor Fitzgerald initiated coverage of Eli Lilly ... Doing? Lilly Endowment holds 96,017K shares representing 10.69% ownership of the company.
Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best American dividend stocks. Dividend-paying stocks have long benefited investors by ...
In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best American dividend stocks. Dividend-paying stocks have long benefited investors by ...
Eli Lilly and Novo Nordisk dominate the billion ... the results still represent a big win for Lilly. The company says it will submit orforglipron for weight management to regulators for review ...
From late 2020 to the summer of 2024, Eli Lilly & Co ... Billions Since 2016, Lilly’s revenue grew by 60% but income grew by 91%. Typically, you would not expect a company growing at its ...
Eli Lilly’s shares (LLY) skyrocketed 16% on Thursday, making it the top performer in the S&P 500, after the company released positive clinical trial data for its experimental oral weight-loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results